P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress

BACKGROUND: TMZ with short course radiotherapy (RT) is an option for elderly GBM patients. Nivolumab is a PD-1 inhibitor with known safety profile in GBM. An increase of mutations as we age is well documented in GBM and in cancer in general. A higher mutational load is associated with increased resp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Khasraw, M, McDonald, K, Yip, S, Verhaak, R G, Heimberger, A B, Hall, M, Barnes, E, Hovey, E, Ellingson, B M, Lwin, Z
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Poster Presentations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144427/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.077
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares